For Investors

Investor Relations

Latest Press Releases

All Press Releases
Date Title
January 8, 2021
Novan to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
December 21, 2020
Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program
December 15, 2020
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
November 4, 2020
Novan Receives Approval to Transfer to Nasdaq Capital Market

Recent SEC Filings

All SEC Filings

Upcoming Events

More 
More events are coming soon.

Stock Information

more

Exchange
Volume
Today's Open
Previous Close

Data as of Jan 18, 2021 9:42 AM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

October 21, 2016
October 21, 2016

Corporate Governance

Click here to view our Corporate Governance information.

IR & Media Contact

Information Request

Click here to request information.

Presentation

More
November 2, 2020

Annual Report

More
July 23, 2020

Analyst Coverage

more
Firm Analyst
HC Wainwright & Co.
Oren Livnat, CFA
Zacks Small-Cap Research
John D. Vandermosten, CFA
JMP Securities
Donald Ellis, Pharm.D.

Novan, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Novan, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Novan, Inc. or its management. Novan, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Transfer Agent

E-mail Alerts

  • Sign up here to get latest notifications whenever Novan inc. posts new information to the site.